Durect said that Voyager had ended the trials “in order to get an earlier look at potential efficacy from over 600 accrued patients.”
“We look forward to this early read out of these clinical trials,” said James Brown CEO for Durect. The company did not provide any further comment on the termination of the phase III trial.
Memryte utilizes Durect's proprietary Durin technology to provide sustained release of the drug and is based on Voyager's patented method of treatment of Alzheimer's disease. The Durin biodegradable implant technology is a platform for parenteral delivery of drugs for periods of weeks to six months or more.
Durect currently has five disclosed on-going development programs of which four are in collaboration with pharmaceutical partners.